e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Plasma concentration of isoniazid and rifampin in new tuberculosis patients with and without diabetes mellitus
Parvaneh Baghaei Shiva (Tehran, Islamic Republic of Iran), Parvaneh Baghaei, Payam Tabarsi, Mohammad Reza Masjdei
Source:
International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Session:
Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Session type:
Thematic Poster Session
Number:
2705
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Parvaneh Baghaei Shiva (Tehran, Islamic Republic of Iran), Parvaneh Baghaei, Payam Tabarsi, Mohammad Reza Masjdei. Plasma concentration of isoniazid and rifampin in new tuberculosis patients with and without diabetes mellitus. Eur Respir J 2015; 46: Suppl. 59, 2705
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Related content which might interest you:
Efficacy of treatment of MDR/XDR TB patients with diabetes mellitus
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Effect of diabetes mellitus on the Time of mycobacterial clearance from sputum during the treatment of multi-drugs resistant tuberculosis
Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 2
Year: 2014
Clinical manifestations and efficacy MDR/XDR tuberculosis in patients with different type’s of diabetes mellitus
Source: International Congress 2015 – Case series and clinical conundrums in TB
Year: 2015
Efficacy of moxifloxacin in TB resistant to isoniazid
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Impact of diabetes mellitus on drug-resistant tuberculosis treatment outcomes in Georgia – Cohort study
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in newly diagnosed pulmonary TB
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016
Tuberculosis with diabetes mellitus: Does delayed sputum conversion always needs MDR evaluation?
Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1
Year: 2014
Comparison of the clinical manifestations of tuberculosis in patients with different type’s of diabetes mellitus and without it
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016
Factors associated with severity of pulmonary tuberculosis and mortality in TB patients with diabetes mellitus
Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1
Year: 2014
Impact of diabetes mellitus on clinical parameters and treatment outcomes of diagnosed pulmonary tuberculosis patients
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1
Year: 2014
Screening of diabetes mellitus among new cases of tuberculosis
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013
Tuberculosis and diabetes mellitus: Treatment outcomes using directly observed therapy (DOT)
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015
Clinical experience of clofazimine in the treatment of MDR-TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Effectiveness of lung surgery in MDR TB patients with diabetes mellitus
Source: International Congress 2016 – Open problems in thoracic surgery
Year: 2016
Reduced moxifloxacin exposure in patients with tuberculosis and diabetes
Source: Eur Respir J, 54 (3) 1900373; 10.1183/13993003.00373-2019
Year: 2019
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Outcomes among patients with pulmonary TB with diabetes mellitus treated with anti-TB drugs of 1
st
line
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010
Influence of diabetes mellitus on sputum conversion rate in pulmonary tuberculosis and on antituberculous drug resistance
Source: International Congress 2019 – Tuberculosis and comorbidities
Year: 2019
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis
Source: Annual Congress 2012 - Tuberculosis: clinical findings III
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept